Nachrichten zur Abbvie Inc. Aktie

AbbVie: Humira bald nicht mehr Nummer Eins? Aktienanalyse

Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt in…

AbbVie hikes full-year earnings guidance as Humira sales top estimates By Investing.com

AbbVie hikes full-year earnings guidance as Humira sales top estimates…

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups 24 EPS View

AbbVies (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.…

AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?

The big pharma companys top drug is losing ground, but its dividend keeps rising.…

AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? @themotleyfool #stocks $ABBV $AZN $CVS $UNH $ABT $BGNE $CI $RVNC

The big pharma companys top drug is losing ground, but its dividend keeps rising.…

AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?

Investor focus will likely be on sales of AbbVies (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter…

GoodRx offers exclusive discount to biosimilar targeting AbbVie’s Humira

…

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

…

AbbVie Announces New UK Vice President and General Manager

For UK trade and national media · Steve Hopkinson has been appointed UK Vice President and General Manager with…

AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant…

Analyst Report: AbbVie Inc

…

AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?

Investors who own AbbVies (ABBV) stock may stay invested as the company has faced its biggest challenge, Humiras patent cliff-…

Top Stock Reports for Novo Nordisk, AbbVie & AstraZeneca

Todays Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and…

Auszeichnung für ein sicheres und gesundes Arbeitsumfeld

Ludwigshafen (ots) - Ursa-Chemie und AbbVie gewinnen Responsible Care Preis 2024Die chemisch-pharmazeutische Branche zeigt seit Jahren mit der Initiative "Responsible…

Auszeichnung für ein sicheres und gesundes Arbeitsumfeld

Chemieverbände Rheinland-Pfalz: Ludwigshafen (ots) - Ursa-Chemie und AbbVie gewinnen Responsible Care Preis 2024 Die chemisch-pharmazeutische Branche zeigt seit Jahren mit…

AbbVie Q2 Preview: Upgrade To Buy - Better Late Than Never

…

AbbVie cuts 2024 profit forecast on R&D expenses By Reuters

AbbVie cuts 2024 profit forecast on R&D expenses…

AbbVie cuts 2024 profit forecast on acquisition-related expenses

AbbVie on Wednesday lowered its 2024 adjusted profit forecast as the drugmaker expects to incur $937 million in acquisition-related expenses.…

AbbVie: A Hold Again (Rating Downgrade)

…

Global Allergy Therapeutics Market Size To Exceed USD 42.5 Billion By 2033 | CAGR Of 6.29%

The Global Allergy Therapeutics Market Size was Valued at USD 23.1 Billion in 2023 and the Worldwide Allergy Therapeutics Market…

AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drugs Expanded Use

AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with…

Pharma Stock Roundup: FDAs CRL to MRK & ABBV, Phase III Study Failures for NVO, AZN

FDA rejects Merck (MRK) and AbbVies (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures.…

AbbVies (ABBV) Celsius Therapeutics Deal to Boost IBD Presence

AbbVies (ABBV) acquisition of Celsius Therapeutics is set to add the latters lead pipeline candidate, CEL383, a potential first-in-class TREM1…

Genmab, AbbVie win FDA nod for relapsed follicular lymphoma therapy

…

Can AbbVie Stock Keep Outpacing the S&P 500?

AbbVie has been a surprisingly strong performer of late. Can the stock keep it up?…

Can AbbVie Stock Keep Outpacing the S&P 500? @themotleyfool #stocks $ABBV

AbbVie has been a surprisingly strong performer of late. Can the stock keep it up?…

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock…

AbbVie (ABBV) Parkinsons Candidate Faces 2nd FDA Rejection

AbbVie (ABBV) issues the second CRL for Parkinsons disease medicine, ABBV-951, based on some observations on inspection of one of…

Global Contraceptive Drugs Market Size To Worth USD 40.08 Billion By 2033 | CAGR Of 8.02%

The Global Contraceptive Drugs Market Size was Valued at USD 18.53 Billion in 2023 and the Worldwide Contraceptive Drugs Market…

Global Parkinson’s Disease Treatment Market Size To Worth USD 9.14 Billion By 2033 | CAGR Of 6.41%

The Global Parkinsons Disease Treatment Market Size was Valued at USD 4.91 Billion in 2023 and the Worldwide Parkinsons Disease…

AbbVie sets quarterly dividend at $1.55 per share By Investing.com

AbbVie sets quarterly dividend at $1.55 per share…

AbbVie declares $1.55 dividend

…

Pharma Stock Roundup: FDA Nod to MRKs New Jab & Expanded Use of ABBV & AZN Drugs

FDA approves Mercks (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use of AbbVies (ABBV) Skyrizi and AstraZenecas (AZN)…

AbbVie: Stabübergabe in der Immunologie - Aktienanalyse

Wien (www.aktiencheck.de) - AbbVie-Aktienanalyse von der Raiffeisen Bank International AG: Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), nimmt die…

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking…

AbbVies (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis

AbbVies (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.…

AbbVie: 5 Reasons That Make A Buy Case

…

AbbVie: Neues Kursziel - Aktienanalyse

Minneapolis (www.aktiencheck.de) - AbbVie-Aktienanalyse von Piper Sandler: Piper Sandler erhöht in einer aktuellen Aktienanalyse das Kursziel für die Aktie von AbbVie…

Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%

The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size…

Global Prostate Health Market Size To Worth USD 78.03 Billion By 2033 | CAGR Of 9.12%

The Global Prostate Health Market Size was Valued at USD 32.6 Billion in 2023 and the Worldwide Prostate Health Market…

CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into the $45 Merger Offer, Contact the Firm About Your Rights

NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…

AbbVies tight grip on Humira market raises concerns about biosimilars By Reuters

AbbVies tight grip on Humira market raises concerns about biosimilars…

AbbVies (ABBV) Ovarian Cancer Therapy Meets Study Goal

Data from a mid-stage study shows that treatment with AbbVies (ABBV) Elahere achieves an objective response rate of almost 52%…

Pharma Stock Roundup: LLYs CFO Departs, ABBV, AZN Drugs Get CHMP Approval

Eli Lillys (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVies (ABBV) Skyrizi and AstraZenecas (AZN) Tagrisso.…

AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

The late-stage study will evaluate AbbVies (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at…

S&P 500-Wert AbbVie-Aktie: So viel Gewinn hätte eine Investition in AbbVie von vor einem Jahr abgeworfen

Heute vor 1 Jahr wurden AbbVie-Anteile wochenend-bedingt nicht via Börse NYSE gehandelt. Der Schlusskurs der AbbVie-Aktie betrug am vorangegangen…

AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU

AbbVie (ABBV) announces that the EMAs CHMP issued a positive opinion on its regulatory filing seeking label expansion for the…

CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation into the $45 Merger Offer

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating…

Global Dyspepsia Drugs Market Size To Worth Exceed USD 14.7 Billion By 2033 | CAGR Of 4.46%

The Global Dyspepsia Drugs Market Size was Valued at USD 9.5 Billion in 2023 and the Worldwide Dyspepsia Drugs Market…

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

…